SOLANA BEACH, Calif., Jan. 13, 2000 (PRIMEZONE) -- Situs Corp., a pioneer of intravesical drug delivery, today announced that its Chief Executive Officer, W. Tate Scott, has been appointed to the Board of Directors of the National Association for Continence (NAFC).
NAFC is a not-for-profit organization dedicated to improving the lives of people with bladder control problems. Based in Spartanburg, SC, NAFC, with more than 130,000 members nationwide, is a leader in providing educational materials to consumers and health care professionals alike. NAFC's mission is to increase public awareness about bladder control problems, which affect as many as 25 million Americans, to destigmatize the condition, and to advocate on behalf of sufferers.
"I am both honored and pleased to accept the invitation to join the board of this important organization," Mr. Scott said. "I believe that I, supported by my team at Situs, can make significant contributions to NAFC's mission and we look forward to working together to find solutions for this very challenging condition."
"We are pleased to have Mr. Scott join our Board of Directors," said NAFC Board Chairman Benson F. Smith. "NAFC believes he will be an excellent addition to our already top-notch board, and we look forward to working closely with him in the future."
Situs Corporation is a pioneer of intravesical drug delivery. The company's site-specific drug delivery platform is capable of administering various pharmaceutical compounds for the treatment of local and systemic conditions.
The company's first target indication, overactive bladder, affects an estimated 17 million Americans, more than 30 percent of whom cannot tolerate the side effects of oral medications. Other potential applications of the Situs system include chemotherapeutic agents for bladder cancer, hormones for genitourinary conditions, and analgesics for pain.